NCT01646684View on ClinicalTrials.gov

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 8, 2013

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions
Castration Resistant Prostate Cancer
Interventions
DRUG

SOM230

Trial Locations (4)

10117

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

72076

Novartis Investigative Site, Tübingen

01307

Novartis Investigative Site, Dresden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY